Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 18:17:1171-1182.
doi: 10.2147/JPR.S441180. eCollection 2024.

Perspective on Intradiscal Therapies for Lumbar Discogenic Pain: State of the Science, Knowledge Gaps, and Imperatives for Clinical Adoption

Morgan P Lorio  1 , Jordan Lee Tate  2 , Thomas J Myers  3 , Jon E Block  4 , Douglas P Beall  5
Affiliations

Perspective on Intradiscal Therapies for Lumbar Discogenic Pain: State of the Science, Knowledge Gaps, and Imperatives for Clinical Adoption

Morgan P Lorio et al. J Pain Res. .

Abstract

Specific clinical diagnostic criteria have established a consensus for defining patients with lumbar discogenic pain. However, if conservative medical management fails, these patients have few treatment options short of surgery involving discectomy often coupled with fusion or arthroplasty. There is a rapidly-emerging research effort to fill this treatment gap with intradiscal therapies that can be delivered minimally-invasively via fluoroscopically guided injection without altering the normal anatomy of the affected vertebral motion segment. Viable candidate products to date have included mesenchymal stromal cells, platelet-rich plasma, nucleus pulposus structural allograft, and other cell-based compositions. The objective of these products is to repair, supplement, and restore the damaged intervertebral disc as well as retard further degeneration. In doing so, the intervention is meant to eliminate the source of discogenic pain and avoid surgery. Methodologically rigorous studies are rare, however, and based on the best clinical evidence, the safety as well as the magnitude and duration of clinical efficacy remain difficult to estimate. Further, we summarize the US Food and Drug Administration's (FDA) guidance regarding the interpretation of the minimal manipulation and homologous use criteria, which is central to designating these products as a tissue or as a drug/device/biologic. We also provide perspectives on the core evidence and knowledge gaps associated with intradiscal therapies, propose imperatives for evaluating effectiveness of these treatments and highlight several new technologies on the horizon.

Keywords: allogeneic; autologous; degenerative; disc; discogenic; injection; intradiscal; pain; regenerative.

PubMed Disclaimer

Conflict of interest statement

JT reports grants and/or personal fees from Vivex, Mainstay, Abbott, Saluda, and Curonix, during the conduct of the study. JB is an independent advisor to Vivex Biologics and was remunerated for assistance in manuscript development. DPB is a consultant to Mesoblast, DiscGenics, Spine Biorestorative, Orthoson, and Vivex, has received research funding from Mesoblast, Discgenics, Spine Biorestorative, and Vivex, and is on the scientific advisory board of Orthoson, Vivex, and Mesoblast. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Scatterplot showing the relationship between pre-treatment back pain severity and absolute degree of pain improvement at final follow-up. Data are presented in mm with the horizontal line (20 mm) and the diagonal line (30%) representing the absolute and percentage change thresholds, respectively, for clinical success.
See this image and copyright information in PMC

References

    1. Fine N, Lively S, Seguin CA, Perruccio AV, Kapoor M, Rampersaud R. Intervertebral disc degeneration and osteoarthritis: a common molecular disease spectrum. Nat Rev Rheumatol. 2023;19(3):136–152. doi:10.1038/s41584-022-00888-z - DOI - PubMed
    1. Lorio MP, Beall DP, Calodney AK, Lewandrowski KU, Block JE, Mekhail N. Defining the patient with lumbar discogenic pain: real-world implications for diagnosis and effective clinical management. J Pers Med. 2023;13(5):821. doi:10.3390/jpm13050821 - DOI - PMC - PubMed
    1. Bogduk N. Degenerative joint disease of the spine. Radiol Clin North Am. 2012;50(4):613–628. doi:10.1016/j.rcl.2012.04.012 - DOI - PubMed
    1. Bogduk N. On the definitions and physiology of back pain, referred pain, and radicular pain. Pain. 2009;147(1–3):17–19. doi:10.1016/j.pain.2009.08.020 - DOI - PubMed
    1. Manchikanti L, Singh V, Pampati V, et al. Evaluation of the relative contributions of various structures in chronic low back pain. Pain Physician. 2001;4(4):308–316. doi:10.36076/ppj.2001/4/308 - DOI - PubMed